<DOC>
	<DOCNO>NCT01535443</DOCNO>
	<brief_summary>Study evaluate safety tolerability PRO-155 Ophthalmic Solution 0.09 % healthy volunteer .</brief_summary>
	<brief_title>Safety Tolerability PRO-155 Ophthalmic Solution 0.09 % Healthy Volunteers .</brief_title>
	<detailed_description>A phase I , open label unicentric clinical trial evaluate safety tolerability PRO-155 Ophthalmic Solution 0.09 % healthy volunteer .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Healthy male female . Age â‰¥ 18 year old screening visit Any ocular systemic condition . Patient one blind eye . Visual acuity 20/40 eye . Use ocular systemics medication . Contraindications sensitivity component study treatment . Contact lens user . Ocular surgery within past 3 months.. Women use effective mean contraception pregnant nursing . Participation study investigational drug within 90 day previous inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>PRO-155</keyword>
	<keyword>Ocular NSAIDs</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Ocular Inflammation</keyword>
	<keyword>Ocular Paint</keyword>
</DOC>